🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Nice work by van Gils today (Mo1259) Digestive Disease Week showing that gas and bloating are ubiquitous in #IBS.

Yesterday my dear friend Dr Max Schmulson from Mexico City presented some of his latest findings that #IBS patients have evidence of oxidative stress (Su1777). The physiology of IBS is coming together. This nicely jives with some findings we are presenting tomorrow.

Today at 3:18pm Dr. Juliana Germano and Ali Rezaie MD MSc are presenting data on the second of three therapeutics for #SIBO/#IMO. In this study, the palatable elemental diet reduces #methane rapidly and reduces M. Smithii in the #microbiome. This helps #constipation. Great work by our

Today at 4:30 pm I am excited to present the data Digestive Disease Week from MAST Research Program on the third treatment. Rifaximin low dose in with NAC improves #IBS-D stool frequency better than the FDA approved dose alone. Hydrogen sulfide appears linked to the response. 1/2

Furthermore, the microbiome is not damaged by the treatment and the main known bad actors in #IBS/#SIBO/#ISO (Klebsiella, E. coli, fusobacterium and desulfovibrio) are preferentially reduced. Phase IIB study starts in a few weeks. #hope 2/2

Today at 12:30, (Mo1405) Ali Rezaie MD MSc Gabriela Leite, PhD Ruchi Mathur MD and MAST Research Program present the second work on the massive 6000 patient nationwide three gas breath test study. Bloating is most common reason for test. Hydrogen sulfide is associated with more severe #diarrhea.

Looking forward to abstract Mo1412 from Dr Kennedy at UT southwestern today at 12:30. Also studying the importance of three gas breath testing and hydrogen sulfide. But also the benefits after treatment.

On another note, Dr Jonathan Busam is presenting at 12:30 (Mo1287) today a meta-analysis of harm with #IBS drugs. The most dropouts from side effects were seen with tricyclic antidepressants, alosetron and tenapanor. The most safe were rifaximin and ramosetron. Interestingly, for

Wow! Great talk on Spatial Transcriptomics.

Finally, so many scientists looking as small bowel microbiome Digestive Disease Week using good improving techniques. Not single lumen catheters.

Final day Digestive Disease Week. Today Dr Juliana Germano from our MAST Research Program presents an amazing study showing how having hydrogen sulphide on your breath testing is associated with dramatic changes in your small intestinal function. 1/2

2/2 including mitochondrial changes, oxidative stress, changes in gut sensory function, motility and fluid secretion. Common findings in #IBS. This is at 9 am.

Today, lead project scientist Gabriela Leite, PhD from our MAST Research Program, takes us home answering a critical question Digestive Disease Week ...Lactulose or glucose for three gas breath testing? The answer is lactulose for SIBO based on 6000 three gas breath testing study...but come and see why

Research presented at Digestive Disease Week by Mark Pimentel MD and colleagues Cedars-Sinai showed that rifaximin plus N-acetylcysteine outperformed rifaximin alone in improvements in pain, bloating and diarrhea among patients with IBS-D. #BeGutsy #IBS #DDW25 🦠💊 bit.ly/4jNOXXu

Thanks @heliogastro for covering this story. Many exciting new developments in the #microbiome of #IBS are now coming. Low-dose rifaximin plus N-acetylcysteine superior to rifaximin alone in IBS-diarrhea healio.com/news/gastroent…

Summary of MAST Research Program work at #DDW2025 1. Low dose rifaximin+NAC better than rifaximin in #IBS-D. Hydrogen sulfide is indicator 2. Nationwide three gas breath test study proves link between H2S and diarrhea, methane and constipation 3. New drug reduces methane and constipation

2/2 4. Transcriptomics shows the damaging effects of #SIBO, #IMO and mostly #ISO (hydrogen sulfide) on the small intestine 5. Lactulose is better than glucose for three gas breath test 6. Elemental diet is an effective option to treat #SIBO and #IMO

This past #DDW2025 reminded me of article showing that #IBS develops after military deployment. Extreme stress was seen in combat but was NOT the risk for IBS. It was food poisoning during combat. IBS is a post-infection event changing the gut microbiome. link.springer.com/article/10.100…

🚨 We're hiring! GI motility program Cedars-Sinai is looking for a Clinical Dietitian II to join our multi-disciplinary neurogastromotility team. Passionate about gut health, microbiome, nutrition, and trailblazing innovation? This role is for you. 🔗 careers.cshs.org/job/beverly-hi…

This was a great year! Just recovering from an amazing DDW and gearing up for the next academic funding cycle starting in July. As you can imagine it's different this year. Trying to continue our momentum since we now have the right drugs and targets.